Network pharmacology analysis predicted that the PI3K/AKT signaling pathway is critical for BBEA's anti-RA activity, and molecular docking confirmed strong binding affinities between key components (e.g., Genkwanin) and core targets (SRC, AKT1). This evidence concerns the gene AKT1 and rheumatoid arthritis.